Literature DB >> 20371788

Acute care utilization and rehospitalizations for sickle cell disease.

David C Brousseau1, Pamela L Owens, Andrew L Mosso, Julie A Panepinto, Claudia A Steiner.   

Abstract

CONTEXT: Published rates of health care utilization and rehospitalization by people with sickle cell disease have had limited generalizability and are not population based.
OBJECTIVE: To provide benchmark data for rates of acute care utilization and rehospitalizations for patients with sickle cell disease.
DESIGN: Retrospective cohort of sickle cell disease-related emergency department (ED) visits and hospitalizations from select states in the 2005 and 2006 Healthcare Cost and Utilization Project (HCUP) State Inpatient Databases and State Emergency Department Databases.
SETTING: Eight geographically dispersed states (Arizona, California, Florida, Massachusetts, Missouri, New York, South Carolina, and Tennessee) that provide encrypted identifiers and have sufficient numbers of patients with sickle cell disease; together these states have 33% of the US population with sickle cell disease. PATIENTS: A total of 21,112 patients with sickle cell-related treat-and-release ED visits or inpatient hospitalizations. MAIN OUTCOME MEASURES: Rates of acute care utilization and rehospitalizations. Population-based utilization rates were also calculated.
RESULTS: The 21,112 people with sickle cell disease had 109,344 encounters, a mean of 2.59 (95% confidence interval [CI], 2.53-2.65) encounters per patient per year, 1.52 (95% CI, 1.48-1.55) encounters for hospitalizations and 1.08 (95% CI, 1.04-1.11) for treat-and-release ED visits. Utilization was highest for 18- to 30-year-olds, 3.61 (95% CI, 3.47-3.75) encounters per patient per year, and those with public insurance, 3.22 (95% CI, 3.13-3.31) encounters per patient per year. Publicly insured 18- to 30-year-olds had 4.80 (95% CI, 4.58-5.02) encounters per patient per year. Approximately 29% of the population had no encounters while 16.9% had 3 or more encounters per year. The 30-day and 14-day rehospitalization rates were 33.4% (95% CI, 33.0%-33.8%) and 22.1% (95% CI, 21.8%-22.4%), respectively. The rehospitalization rate was highest for 18- to 30-year-olds, with 41.1% (95% CI, 40.5%-41.7%) rehospitalized within 30 days and 28.4% (95% CI, 27.8%-29.0%) within 14 days. Rehospitalizations were also highest for publicly insured patients.
CONCLUSION: Among patients with sickle cell disease, acute care encounters and rehospitalizations were frequent, particularly for 18- to 30-year-olds.

Entities:  

Mesh:

Year:  2010        PMID: 20371788     DOI: 10.1001/jama.2010.378

Source DB:  PubMed          Journal:  JAMA        ISSN: 0098-7484            Impact factor:   56.272


  213 in total

1.  Psychometric Properties of the Psychosocial Assessment Tool-General in Adolescents and Young Adults With Sickle Cell Disease.

Authors:  Lori E Crosby; Naomi E Joffe; Nina Reynolds; James L Peugh; Ellen Manegold; Ahna L H Pai
Journal:  J Pediatr Psychol       Date:  2015-08-13

2.  Association between hospital admissions and healthcare provider communication for individuals with sickle cell disease.

Authors:  Robert M Cronin; Manshu Yang; Jane S Hankins; Jeannie Byrd; Brandi M Pernell; Adetola Kassim; Patricia Adams-Graves; Alexis A Thompson; Karen Kalinyak; Michael DeBaun; Marsha Treadwell
Journal:  Hematology       Date:  2020-12       Impact factor: 2.269

3.  CE: Understanding the Complications of Sickle Cell Disease.

Authors:  Paula Tanabe; Regena Spratling; Dana Smith; Peyton Grissom; Mary Hulihan
Journal:  Am J Nurs       Date:  2019-06       Impact factor: 2.220

4.  Dexmedetomidine ameliorates nocifensive behavior in humanized sickle cell mice.

Authors:  Gabriela Calhoun; Li Wang; Luis E F Almeida; Nicholas Kenyon; Nina Afsar; Mehdi Nouraie; Julia C Finkel; Zenaide M N Quezado
Journal:  Eur J Pharmacol       Date:  2015-02-25       Impact factor: 4.432

5.  Understanding the Self-Management Practices of Young Adults with Sickle Cell Disease.

Authors:  Nadine Matthie; Coretta Jenerette
Journal:  J Sick Cell Dis Hemoglobinopathies       Date:  2017-05

6.  Changes in Pain and Psychosocial Functioning and Transition to Chronic Pain in Pediatric Sickle Cell Disease: A Cohort Follow-up Study.

Authors:  Soumitri Sil; Lindsey L Cohen; Nitya Bakshi; Amanda Watt; Morgan Hathaway; Farida Abudulai; Carlton Dampier
Journal:  Clin J Pain       Date:  2020-06       Impact factor: 3.442

Review 7.  Key Components of Pain Management for Children and Adults with Sickle Cell Disease.

Authors:  Amanda M Brandow; Michael R DeBaun
Journal:  Hematol Oncol Clin North Am       Date:  2018-06       Impact factor: 3.722

8.  Development and evaluation of iManage: A self-management app co-designed by adolescents with sickle cell disease.

Authors:  Lori E Crosby; Russell E Ware; Alana Goldstein; Ashley Walton; Naomi E Joffe; Craig Vogel; Maria T Britto
Journal:  Pediatr Blood Cancer       Date:  2016-08-30       Impact factor: 3.167

9.  Mechanism-driven phase I translational study of trifluoperazine in adults with sickle cell disease.

Authors:  Robert E Molokie; Diana J Wilkie; Harriett Wittert; Marie L Suarez; Yingwei Yao; Zhongsheng Zhao; Ying He; Zaijie J Wang
Journal:  Eur J Pharmacol       Date:  2013-11-07       Impact factor: 4.432

10.  Venous thromboembolism in adults with sickle cell disease: a serious and under-recognized complication.

Authors:  Rakhi P Naik; Michael B Streiff; Carlton Haywood; Julie A Nelson; Sophie Lanzkron
Journal:  Am J Med       Date:  2013-05       Impact factor: 4.965

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.